Table 3.
Rate and risk of outcome events according to baseline cerebral microbleeds in patients treated with oral anticoagulants with or without antiplatelet drugs (n=7737)
|
Composite of intracranial haemorrhage and ischaemic stroke (n=7582 for multivariable model) |
Symptomatic intracranial haemorrhage (n=6942 for multivariable model) |
Symptomatic ischaemic stroke (n=6958 in multivariable models) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Rate, per 1000 patient-years* | Absolute rate increase, per 1000 patient-years | Adjusted hazard ratio | Rate, per 1000 patient-years | Absolute rate increase, per 1000 patient-years | Adjusted hazard ratio | Rate, per 1000 patient-years | Absolute rate increase, per 1000 patient-years | Adjusted hazard ratio | ||
| None | 31 (28 to 35) | .. | 1 (ref) | 5 (3 to 6) | .. | 1 (ref) | 27 (23 to 30) | .. | 1 (ref) | |
| Any | 46 (39 to 53) | 15 (11 to 18) | 1·30 (1·07 to 1·57) | 12 (9 to 16) | 7 (6 to 10) | 2·49 (1·64 to 3·79) | 32 (26 to 39) | 5 (3 to 9) | 1·07 (0·86 to 1·35) | |
| One | 38 (30 to 49) | 7 (2 to 14) | 1·19 (0·91 to 1·56) | 10 (6 to 17) | 5 (3 to 11) | 2·15 (1·23 to 3·75) | 26 (19 to 35) | −1 (−4 to 5) | 0·96 (0·69 to 1·33) | |
| Number | ||||||||||
| Two to four | 47 (36 to 60) | 16 (8 to 25) | 1·23 (0·93 to 1·62) | 11 (6 to 19) | 6 (3 to 13) | 2·22 (1·21 to 4·06) | 36 (26 to 48) | 11 (3 to 18) | 1·10 (0·80 to 1·52) | |
| Five or more† | 62 (45 to 84) | 31 (17 to 49) | 1·69 (1·22 to 2·35) | 20 (11 to 34) | 15 (8 to 28) | 3·91 (2·08 to 7·34) | 40 (26 to 59) | 13 (3 to 29) | 1·27 (0·84 to 1·91) | |
| Ten or more† | 75 (46 to 116) | 44 (18 to 81) | 2·15 (1·35 to 3·43) | 23 (8 to 50) | 18 (5 to 44) | 4·63 (1·92 to 11·22) | 46 (24 to 81) | 19 (1 to 51) | 1·52 (0·84 to 2·67) | |
| Anatomical distribution | ||||||||||
| Mixed | 58 (42 to 77) | 27 (14 to 42) | 1·43 (1·02 to 2·00) | 15 (7 to 26) | 10 (4 to 20) | 2·21 (1·09 to 4·47) | 42 (29 to 60) | 15 (6 to 30) | 1·28 (0·85 to 1·94) | |
| Deep | 52 (42 to 63) | 21 (14 to 28) | 1·43 (1·11 to 1·84) | 14 (9 to 21) | 9 (6 to 15) | 2·71 (1·61 to 4·59) | 35 (27 to 46) | 8 (4 to 16) | 1·16 (0·85 to 1·59) | |
| Lobar | 41 (32 to 51) | 10 (4 to 16) | 1·13 (0·87 to 1·47) | 10 (6 to 16) | 5 (3 to 10) | 1·63 (0·94 to 2·83) | 29 (22 to 38) | 2 (−1 to 8) | 1·00 (0·73 to 1·38) | |
| Probable cerebral amyloid angiopathy | 27 (13 to 47) | −4 (−15 to 12) | 0·76 (0·41 to 1·39) | 10 (3 to 25) | 5 (0 to 19) | 1·29 (0·47 to 3·57) | 17 (7 to 35) | −10 (−16 to 5) | 0·64 (0·30 to 1·37) | |
Ranges in brackets are 95% CIs. Cerebral microbleed location hazard ratios are versus patients without cerebral microbleeds in each location and are adjusted for cerebral microbleed number and our prespecified variables.
*
Number of patients and time at risk are shown in the appendix.
†
Overlapping categories.